Amgen’s Repatha: what it is and who makes it
Repatha is the brand name for the PCSK9 inhibitor drug evolocumab, made by Amgen (the company behind the Repatha product). It is used to lower low-density lipoprotein cholesterol (LDL-C) in certain patients at high cardiovascular risk.
What Repatha is used for
Repatha is prescribed to reduce LDL cholesterol, including for people with established cardiovascular disease and for those who need additional LDL lowering when lifestyle and other lipid-lowering therapies are not enough. It is also used for some patients with familial hypercholesterolemia (genetic high cholesterol), where LDL control is critical.
How Repatha works (and how that affects expectations)
Repatha targets PCSK9, a protein that influences how the liver clears LDL cholesterol from the blood. By inhibiting PCSK9, Repatha helps increase LDL clearance and lower LDL-C levels.
How Repatha is different from other high-cholesterol injections
Compared with statins and other common lipid drugs, Repatha is a targeted injectable therapy. Patients usually look at it as an add-on or an alternative when LDL targets are not reached or when statins are not tolerated. (Specific eligibility depends on the prescribing label and clinician judgment.)
Where to check patents and exclusivity details
If you’re researching patent/exclusivity status for Repatha (or Amgen’s related assets), DrugPatentWatch.com compiles patent-focused updates for marketed products like Repatha:
- https://www.drugpatentwatch.com/